PUBLISHER: Grand View Research | PRODUCT CODE: 1571672
PUBLISHER: Grand View Research | PRODUCT CODE: 1571672
The global bronchial biopsy devices market size is expected to reach USD 1.02 billion by 2030, growing at a CAGR of 7.39% from 2024 to 2030, according to a new report by Grand View Research, Inc. One of the major factors contributing to the growth of the market is the rising utilization of bronchial biopsy devices for diagnosing respiratory diseases and the increasing adoption of disposable devices. Moreover, rapid technological advancements and increasing awareness and screening regarding respiratory diseases also contribute to market expansion.
Advancements in medical technology are significantly driving the growth of the market by improving the precision, safety, and effectiveness of diagnostic procedures. Innovations such as EBUS-TBNA enable more accurate sampling of lung tissue, especially in difficult-to-reach areas. These minimally invasive techniques minimize patient discomfort, reduce the risk of complications, and shorten recovery times compared to traditional surgical methods. In addition, companies are entering the market with technologically advanced products to establish a strong presence. For instance, in May 2021, Olympus launched the BF-UC190F endobronchial ultrasound (EBUS) bronchoscope for lung cancer diagnosis and staging, thereby expanding its product portfolio.
Moreover, the increasing awareness and screening initiatives led by various organizations are significantly driving the demand for bronchial biopsy devices. With lung cancer being one of the most prevalent and deadly forms of cancer globally, organizations such as the American Lung Association and the WHO have intensified their efforts to promote early detection and diagnosis. In August 2024, in recognition of World Lung Cancer Day, the Forum of International Respiratory Societies, with the Global Initiative for Asthma as a founding member, emphasized the critical need for increased awareness, early screening, and improved access to lung cancer diagnosis & treatment.
Furthermore, the COVID-19 pandemic had a moderately negative impact on the bronchial biopsy device market, as evidenced by the disruption in lung cancer diagnosis and treatment observed during the early months of the pandemic. According to a study conducted by Elsevier Espana SLU, in July 2021, at a referral University Hospital in Spain, the mandatory confinement from March 23rd to June 21st, 2020, led to a substantial decrease in the number of lung cancer diagnoses. This decline was attributed to the cancellation or delay of medical consultations, diagnostic tests, and non-essential procedures, which resulted in a reduced number of lung biopsies & screening visits.